

p53 TUMOUR SUPPRESSOR GENE IN LUNG CANCER

THESIS

Submitted for partial fulfillment of
M.D Degree in Chest Diseases

on
Disk

Handwritten signature

By

Emad ElDeen Abd-ElWahab KORRAA

Handwritten signature

Supervised By

60751

Prof. Hussein Aly Hussein
Prof. of Chest Diseases
Ain Shams University

Prof. Adel Gomaa Ali
Prof. of Chest Diseases
Ain Shams University

Prof. Mohammed Ahmed Attia
Prof. of Virology and Immunology
National Cancer Institute
Cairo University

Prof. Hussein Moustafa Khaled
Prof. of Medical Oncology
National Cancer Institute
Cairo University

616.99424

E. E

Prof. Jean Claude Kouyoumdjian


Prof. of Biochemistry
Paris XII University

Handwritten signature

Handwritten signature

Handwritten signature

Faculty of Medicine
Ain Shams University
1999



Acknowledgment

I would like to convey my particular thanks and deepest gratitude to **Prof. Dr. Hussein Aly Hussein** Professor of Chest Diseases, Ain Shams University, for his keen supervision and precious instructions.

I am really indebted to **Prof. Dr. Adel Gomaa**, Professor of Chest Diseases, Ain Shams University for his close supervision and suggestion of the subject of this thesis. A good chance to express such for his continuous encouragement throughout the whole work.

I wish to express my gratitude and thanks to **Prof. Dr. Mohamed Ahmed Attia**, Professor of Virology and Immunology, Tumour Biology Department, National Cancer Institute, Cairo University, for his supervision and cooperation.

May I also express my profound appreciation and gratitude for **Prof. Dr. Hussein Khalid**, Professor of Medical Oncology, National Cancer Institute, Cairo University, for his keen supervision, suggestion of the protocol and also for his criticism that was always indispensable and instigating.

The credit of bringing this work to light goes to my **Prof. Dr. J. C. Kouyoumdjian**, Professor of Biochemistry, Henri Mondor hospital, Paris XII University, for his close supervision of the experimental work, great kindness and valuable cooperation which made this study possible.



LIST OF TABLES

Table No.	Title	Page
1	Age adjusted incidence of lung cancer per 100,000	4
2	Age adjusted death rates per 100,000 population for the 10 countries with greatest incidence of lung cancer	5
3	Extent of the disease at time of diagnosis and 5-year survival rates by stage and diagnosis	5
4	Major mutagens, carcinogens, and related substances in tobacco smoke	7
5	List of occupations associated with higher incidence of lung cancer	11
6	Different cancer types and their risks at relatives	12
7	Local Tumour Symptoms	31
8	Bronchoscopic diagnosis of lung cancer	43
9	Reports of radiotherapy for T1 and T2 tumours	62
10	Reports of radiotherapy for T1 and T2 tumours	68
11	Active drugs in NSCLC with their response rates	69
12	Response rates for some combination chemotherapy	70
13	Prognostic factors in SCLC	73
14	Classification of single agent chemotherapy	74
15	Retroviral Oncogenes	90
16	partial list of proto-oncogenes with their protein function and location in the cell	93
17	Examples of oncogenes consistently mutated in human cancers and the type of mutations in each	95
18	Clinically important proto-oncogenes and oncogenes in lung cancer	97
19	Partial list of antioncogenes	109
20	Properties of p53 wild-type and mutant allele	119

- 21** p53 g
- 22** p53 g
exons
- 23** Sequ
- 24** Clinic
dysp:
- 25** Clinic
cancer
- 26** Resu
band
- 27** Resu
band
- 28** Corre
of pa
- 29** Corre
patie
- 30** Corre
smok
- 31** Corre
and s
- 32** Corre
smok
- 33** Corre
types
- 34** Correlat
types of
- 35** Correlat
types
- 36** Corre
types
- 37** Corre
types

38	Correlation between p53 mutations and the extensive and limited diseases of SCLC	175
39	Correlation between p53 mutations and tumour size (T), lymph nodal involvement (N) and presence of metastases (M)	175
40	Correlation between p53 mutations and age of cases in group II	176
41	Correlation between p53 status and sex of group II cases	176
42	Correlation between p53 mutations and smoking index in group II cases	177
43	Correlation between transversion mutations of p53 and smoking index in group II cases	177
44	Correlation between other mutations of p53 and smoking index in group II cases	177
45	Correlation between p53 mutations and histological grading of dysplasia	178
46	p53 status in the dysplasia and the lung cancer groups	178



LIST OF FIGURES

Figure No.	Title	Page
1	The fundamental features of cellular regulation	88
2	The p53 response	115
3	p53 DNA	116
4	Multistep process of lung carcinogenesis: sequential molecular and genetic abnormalities in parallel with morphological changes	125
5	Multistep process of lung carcinogenesis: sequential molecular and genetic abnormalities in parallel with morphological changes	152
6	Results of the uniplex PCR for some exons 2 & 3 in some samples	153
7	Results of the SSCP reaction for some exons of some samples	155
8	Frequencies and types of p53 mutations in group II	160
9	Frequency of mutational events in group II	161
10	Distribution of mutations at p53 exons in group II cases	161
11	Distribution of mutations at p53 codons in group II cases	162
12	Frequency of types of p53 mutations in group III	162
13	Frequency of mutational events in group III	163
14	Distribution of mutations at p53 exons in group III cases	164
15	Distribution of mutations at p53 codons in group III cases	164
16	Frequency and types of p53 mutations in SCLC	168
17	Frequency and types of p53 mutations in NSCLC	168


18	Frequency of p53 mutations events in SCLC	169
19	Distribution of mutations at p53 exons in SCLC	169
20	Distribution of mutations at p53 codons in SCLC	170
21	Frequency of p53 mutations events in NSCLC	170
22	Distribution of mutations at p53 exons in NSCLC	171
23	Distribution of mutations at p53 codons in NSCLC	171

LIST OF ABBREVIATIONS

A	Adenine
bp	Base Pair
BP	Benzo Pyrene
BSC	Best Supportive Care
C	Cytosine
CEA	Carcinoembryonic antigen
CT	Computed Tomography
ddNTP	Dideoxynucleotide
DNA	Deoxyribonucleic Acid
DNAB	DNA Binding Proteins
dNTP	Deoxynucleotide
EBV	Epstein-Barr Virus
EGF	Epidermal Growth Factor
EGFR	Epidermal Growth Factor Receptor
erb-B	Avian Erythroblastosis Virus
fos	FBJ Osteosarcoma Virus
Fu	fluorouracil
G	Guanine
GF	Growth Factor
GFR	Growth Factor Receptor
GP	G protein
GRP	Gastrin Releasing Peptide
HPD	Haematoporphyrin Derivative
HPV	Human Papilloma Virus
H-ras	Harvey Murine Sarcoma
jun	Avian Sarcoma Virus 17
K-ras	Kirsten Murine Sarcoma
LFS	Li-Fraumeni Syndrome
LT	Large Tumour antigen

mdm 2	Murine double minute 2 gene
MER	Methanol extractable residue
MRI	Magnetic Resonance Imaging
myb	Avian Myeloblastosis Virus
myc	Avian Myelocytomatosis Virus
Nd-YAG0	Neodymium Yttrium-aluminium garnet
NSCLC	Non Small Cell Lung Cancer
NSE	Neuron Specific Enolase
PBS	Post-Bronchoscopy Sputum
PCF	Prophylactic Cranial Irradiation
PCR	Polymerase Chain Reaction
PDGF	Platelet Derived Growth Factor
PFNA	Percutaneous Fine Needle Aspiration
P-Gp	P-glycoprotein
PK	Protein Kinase
PS	Performance Status
Rb	Retinoblastoma
RNA	Ribonucleic Acid
SCLC	Small cell Lung Cancer
SIAD	Syndrome of Inappropriate Antidiuretic Hormone secretion
SSCP	Single Strand Conformation Polymorphism
sT	Small Tumour antigen
SV40	Simian Virus 40
SVC	Superior Vena Cava
T	Thymine
T antigen	Tumour antigen
WT-1	Wilms' Tumour gene

Introduction
and Aim of
The Work



Introduction

Less than a century ago, lung cancer was a medical curiosity (*Osler, 1982*). Today, it is the seventh most common tumour in Egypt, contributing 2.8% of all cancers and it is on the increase (*El-Bolkainy, 1991*). In western countries, it is considered as the first oncological problem with frequency of about 16% of all cancers (*Silverberg et al., 1990*).

In spite of the improvement in diagnostic procedures and treatment approaches of lung cancer, most patients still die suffering from this disease (*Fisher and Scoggin, 1986*). However, progress in the science of molecular biology has reached a point where it can provide a basis for new strategies in the prevention, diagnosis and treatment of this disease (*Minna et al., 1986 ; Minna et al., 1990*).

It is now clear that cancer is caused by the malfunction of genes that regulate cell proliferation. Two kinds of regulatory genes have been discovered. Those that promote growth of cells, called oncogenes, and those that suppress growth, called anti-oncogenes or tumour suppressor genes (*Yarbo, 1992*). Accumulating evidence indicates that changes in both oncogenes and tumour suppressor genes are necessary for malignant transformation of normal bronchial epithelial cells (*Suzuki et al., 1992*).

One of the most important tumour suppressor genes involved in the pathogenesis of lung cancer is the gene coding for protein called the p53 gene (*Levine et al., 1991*). Different studies

revealed that mutations of this p53 gene occur in many tumours including lung cancers (*Miller et al., 1992*), and that p53 mutations were the most frequent alterations found in lung cancer (*Zalcman et al., 1994*).

Aim of the work

To evaluate and screen for p53 mutations in bronchoscopic bronchial specimens from patients with bronchogenic carcinoma and bronchial dysplasia and to correlate this with their clinicopathological data.